The U.S. discovers many new medicines, but often cannot make them at large scale at home. This cause supports creating a national Biopharmaceutical Center of Excellence to improve drug manufacturing, train workers, and reduce shortages. Winning means Congress advances and funds the Biomanufacturing Excellence Act so a pilot center can launch.
Why this matters now
When more of the medicine supply chain sits overseas, the U.S. has less control during emergencies and disruptions. COVID-19 exposed how hard it can be to ramp up production fast, and shortages of critical medicines can follow.
A Center of Excellence is meant to rebuild practical “how to manufacture” capacity, not just research. It could help the U.S. make advanced products like biologics, vaccines, and gene therapies more reliably, while training people to run modern manufacturing.